Core Points - The report summarizes the financial performance and operational status of Jilin Xidian Pharmaceutical Technology Development Co., Ltd. for the first half of 2025, highlighting a slight decrease in revenue but an increase in net profit [1][2]. Financial Performance - Operating revenue for the reporting period was CNY 128,311,809.27, a decrease of 0.51% compared to the same period last year [1]. - Net profit attributable to shareholders was CNY 24,944,585.08, reflecting a growth of 2.02% year-on-year [1]. - Net cash flow from operating activities increased by 3.49% to CNY 33,713,141.57 [1]. - Basic earnings per share rose by 7.77% to CNY 0.3261, while diluted earnings per share increased by 5.43% to CNY 0.3261 [1]. - The weighted average return on equity was 2.73%, up from 2.56% in the previous year [1]. Asset and Equity Status - Total assets at the end of the reporting period were CNY 1,055,706,506.89, a decrease of 0.65% from the previous year [1]. - Net assets attributable to shareholders increased by 0.56% to CNY 910,831,590.25 [1]. Shareholder Information - The largest shareholder, Zhang Jun, holds 25.66% of the shares, amounting to 19,627,034 shares [2]. - Other significant shareholders include Dingdian Investment Management (7.86%) and Zhuhai Hengqin Yanhe Health Technology (4.83%) [2][3]. - The report indicates that there are no changes in the controlling shareholder or actual controller during the reporting period [4]. Important Events - The company received approval for several drug applications, including sodium hyaluronate eye drops and antiviral tablets, which may enhance its product portfolio and market position [6].
西点药业: 2025年半年度报告摘要